Investors are turning their attention to Myriad Genetics as the company prepares to release its audited financial results for fiscal year 2025. Following preliminary figures issued in January, the market now awaits detailed confirmation and insights into the company’s clinical development progress. A significant near-term catalyst is the scheduled commercial launch of a new oncology test in March.
Financial Confirmation and Forward Guidance
The upcoming release this month is expected to verify the unaudited fourth-quarter and full-year 2025 results initially shared on January 12. The preliminary data established a solid foundation, with revenue for 2025 projected to land between $822 million and $824 million.
Looking ahead, management has signaled continued expansion for fiscal 2026, providing a revenue forecast ranging from $860 million to $880 million. An analyst conference scheduled for February will be scrutinized for deeper insights into the company’s financial stability and operational margins, which are crucial for supporting current market expectations.
Should investors sell immediately? Or is it worth buying Myriad Genetics?
Strategic Oncology Expansion
A central component of the growth strategy involves precision oncology. Myriad Genetics is targeting a limited clinical launch in March 2026 for “Precise MRD,” a test designed to detect minimal residual disease. The initial focus will be on breast cancer, with plans to expand its application to colorectal and kidney cancers later in the year.
This strategic rollout occurs within a favorable market environment. Industry experts project the global molecular diagnostics market, valued at approximately $17 billion in 2025, will grow to over $28 billion by 2035. This expansion is being driven by technological advancements, including the integration of artificial intelligence and the increasing adoption of liquid biopsy techniques.
A Pivotal Sequence of Events
The imminent publication of final annual figures represents the next key event for evaluating the company’s stock. It will be quickly followed by the clinical debut of Precise MRD in March, a launch that will serve as a critical test of Myriad Genetics’ ability to successfully translate its innovations into clinical practice.
Ad
Myriad Genetics Stock: Buy or Sell?! New Myriad Genetics Analysis from February 7 delivers the answer:
The latest Myriad Genetics figures speak for themselves: Urgent action needed for Myriad Genetics investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 7.
Myriad Genetics: Buy or sell? Read more here...
